Healthcare Services

Critical limb ischemia market to reach $6B by 2030 at 9% CAGR

April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Critical Limb Ischemia Market From 2026 To 2030?

The critical limb ischemia market has experienced substantial growth in recent years. It is projected to expand from $3.89 billion in 2025 to $4.25 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. This historical growth can be linked to the high prevalence of peripheral artery disease, the increasing incidence of diabetes, the expansion of the aging population, a reliance on surgical revascularization, and delayed disease diagnosis.

The critical limb ischemia market is projected to experience robust expansion in the coming years. Its valuation is set to reach $6 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.0%. This anticipated growth during the forecast period is primarily driven by progress in vascular device technology, an increase in minimally invasive procedural approaches, the proliferation of specialized vascular facilities, heightened understanding of the importance of limb preservation, and better availability of diagnostic imaging. Key trends identified for the forecast period encompass a surge in endovascular revascularization uptake, expanded application of drug-eluting devices, the evolution of limb salvage treatment methodologies, the broadening scope of multidisciplinary vascular services, and a heightened emphasis on early detection and timely intervention.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/critical-limb-ischemia-global-market-report

What Primary Drivers Are Shaping The Critical Limb Ischemia Market?

Increased investments in healthcare infrastructure are projected to drive the expansion of the critical limb ischemia treatment market in the coming years. Healthcare infrastructure investment pertains to the allocation of funds for the development, enhancement, and maintenance of vital physical structures, facilities, and systems that facilitate the provision of healthcare services. This type of investment plays a crucial role in critical limb ischemia (CLI) treatment by ensuring the availability of necessary facilities, equipment, and resources for accurate diagnosis and effective management of the condition. For example, in May 2023, a report from the Office for National Statistics, a UK-based government department, revealed that between 2022 and 2023, healthcare spending in the UK grew by 5.6%, which was notably higher than the 0.9% growth recorded in 2022. The UK healthcare expenditure amounted to approximately $317.63 billion (£292 billion) in 2023. Therefore, the rising financial commitments to healthcare infrastructure are a primary factor propelling the growth of the critical limb ischemia treatment market.

How Is The Critical Limb Ischemia Market Categorized Across Its Segment Groups?

The critical limb ischemia market covered in this report is segmented –

1) By Type: Devices, Drugs, Surgery

2) By Medication: Antihypertensive Agents, Antiplatelet Drugs, Antithrombotic Agents, Other Medications

3) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Devices: Angioplasty Balloons, Stents, Catheters, Atherectomy Devices, Implantable Devices

2) By Drugs: Antiplatelet Agents, Vasodilators, Anticoagulants, Thrombolytics, Growth Factors And Cytokines

3) By Surgery: Bypass Surgery, Endarterectomy, Amputation, Revascularization Procedures

What Trends Are Affecting The Growth Of The Critical Limb Ischemia Market?

Leading companies in the critical limb ischemia (CLI) treatment market are developing technologically advanced products, such as dissolving stents, to enhance treatment outcomes for patients afflicted with this severe form of peripheral artery disease. These dissolving stents, also known as bioresorbable stents, are engineered to provide temporary support to the compromised artery before gradually dissolving once the vessel has healed. For instance, in April 2024, Abbott Laboratories, a US-based medical device company, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency, for its Esprit BTK Everolimus Eluting Resorbable Scaffold System. This dissolving stent is specifically designed for patients experiencing chronic limb-threatening ischemia (CLTI) in arteries located below the knee. This approval signifies the first dissolving stent to be authorized for this particular condition in the United States. Composed of materials similar to dissolving sutures, the stent is engineered to progressively dissolve over approximately three years following implantation. It additionally releases the immunosuppressive drug everolimus, which aids in preventing arterial re-narrowing and supports vessel healing.

Which Firms Are Influencing Competition In The Critical Limb Ischemia Market?

Major companies operating in the critical limb ischemia market are Medtronic Plc, Boston Scientific Corporation, Abbott Laboratories, LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc., Shanghai MicroPort Medical (Group) Co Ltd., B. Braun SE, Teva Pharmaceutical Industries Ltd., Cook Medical, Philips, BD, Penumbra Inc., Cardinal Health Inc., Teleflex Incorporated, AngioDynamics Inc., Endologix Inc., Terumo Corporation, MicroPort Scientific, Silk Road Medical, LeMaitre Vascular Inc., Merit Medical Systems Inc., Shockwave Medical, Avinger, Biomerics LLC, Intact Vascular Inc., Bluegrass Vascular Technologies, PQ Bypass, Rex Medical, Aortica Corporation

Get The Full Critical Limb Ischemia Market Report:

https://www.thebusinessresearchcompany.com/report/critical-limb-ischemia-global-market-report

Which Region Leads The Critical Limb Ischemia Market In Overall Market Size?

North America was the largest region in the critical limb ischemia treatment market in 2025. The regions covered in the critical limb ischemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Critical Limb Ischemia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/critical-limb-ischemia-global-market-report

Browse Through More Reports Similar to the Global Critical Limb Ischemia Market 2026, By The Business Research Company

Myocardial Ischemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

Acute Ischemic Stroke Diagnosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-diagnosis-global-market-report

Acute Ischemic Stroke Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795